IMR Press / EJGO / Volume 27 / Issue 5 / pii/2006220

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research

Expression of the epidermal growth factor system in endometrial cancer after adjuvant tamoxifen treatment for breast cancer

Show Less
1 Department of Obstetrics and Gynecology, University of Patras, Medical School, Rion, Greece
2 Department of Pathology, University of Patras, Medical School, Rion, Greece
Eur. J. Gynaecol. Oncol. 2006, 27(5), 490–494;
Published: 10 October 2006
Abstract

The aim of our study was to describe the expression of cerbB-1, cerbB-2, cerbB-3 and cerbB-4 in endometrial cancer tissue and its correlation with clinicopathologic features and prognosis of endometrial cancer patients diagnosed during or after tamoxifen treat­ment for breast cancer. Thirteen tamoxifen-related endometrial cancers were identified from the archives of the Department of Obstetrics and Gynecol­ogy of the University of Patras, Medical School. Tissue specimens from endometrial lesions were immunostained for cerbB-1, cerbB-2, cerbB-3 and cerbB-4. For cerbB-1, five cases were positive and eight were negative. For cerbB-2, ten cases were positive and three were negative. For cerbB-3, nine cases were positive and four were negative. For cerbB-4, eight cases were positive and five were negative. However, a limitation of our study is that the number of cases was small, and further investigations are necessary to allow a more focused evaluation of cerbB-1, cerbB-2, cerbB-3 and cerbB-4 status, as a prognostic factor for endometrial cancer after tamoxifen treatment.

Keywords
Endometrial cancer
Tamoxifen
Breast cancer
Epidermal growth factor system
Cerb-B receptors
Share
Back to top